Skip to content

Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesia-Induced Hypotension

Preoperative Point of Care Ultrasound Guided Fluid Optimization and Intravenous Ondansetron to Prevent General Anesthesia-Induced Hypotension: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05784350
Enrollment
150
Registered
2023-03-24
Start date
2025-08-01
Completion date
2028-05-01
Last updated
2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-operative Hypotension

Brief summary

Hypotension is a common side-effect of general anesthesia induction and is related to adverse outcomes including significantly increasing risk of one-year mortality. Even short durations of intraoperative hypotension have been associated with acute kidney injury (AKI) and myocardial injury.Half of all the patients were fluid-responsive, pointing to volume status as a significant risk factor. Ultrasound measurements of inferior vena cava (IVC) diameter with respiration, including the maximal diameter of the IVC (dIVCmax) at the end of expiration during spontaneous respiration and the collapsibility index (CI), have been recommended as rapid and noninvasive methods for estimating volume status. In attempt to prevent hypotension after spinal anesthesia induction, Ondansetron, a serotonin receptor antagonist, has been used effectively . Research Question Can preoperative IVC-US guided fluid optimization and intravenous ondansetron reduce the incidence of general anesthesia-induced hypotension in adult patients undergoing elective non-cardiac non-obstetric surgery?

Interventions

DRUGfluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone

group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L. Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
19 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age \> 18 2. Elective, non-cardiac, non-obstetric surgery under general anesthesia 3. American Society of Anesthesiologists physical status classification I - III

Exclusion criteria

1. MAP below 60 mmhg prior to the induction of general anesthesia. 2. Patients treated with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) on the day of surgery. 3. Patients with heart failure with ejection fraction (EF) \< 40%. 4. Patients with documented acute or chronic renal failure. 5. Patients with hepatic failure. 6. Patients with neuraxial (spinal/epidural) anesthesia performed before induction of general anesthesia. 7. Patients with suspected difficult airway. 8. Patients with documented allergy to Ondansetron or prolonged QT-syndrome. \-

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia5 yearsTo determine the efficacy of preoperative IVC-guided fluid optimization and intravenous ondansetron in reducing the incidence of hypotension after the induction of general anesthesia in adults presenting for elective non-cardiac, non-obstetric surgery.

Countries

Israel

Contacts

Primary ContactSara Dichtwald, Dr
sara.dichtwald@clalit.org.il972-9-7472133

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026